QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset

K. N. Moore; A. A. Secord; M. Geller; D. S. Miller; N. G. Cloven; G. F. Fleming; A. E. Wahner Hendrickson; M. Azodi; P. DiSilvestro; A. Oza; M. Cristea; J. S. Berek; J. K. Chan; B. J. Rimel; Y. Li; K. Luptakova; R. Clark; U. A. Matulonis; B. J. Monk

doi:10.1093/annonc/mdy285.152

QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset

K. N. Moore, A. A. Secord, M. Geller, D. S. Miller, N. G. Cloven, G. F. Fleming, A. E. Wahner Hendrickson, M. Azodi, P. DiSilvestro, A. Oza, M. Cristea, J. S. Berek, J. K. Chan, B. J. Rimel, Y. Li, K. Luptakova, R. Clark, U. A. Matulonis, B. J. Monk

Medical Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	viii337
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy285.152
State	Published - Oct 1 2018

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdy285.152

Cite this

Moore, K. N., Secord, A. A., Geller, M., Miller, D. S., Cloven, N. G., Fleming, G. F., Wahner Hendrickson, A. E., Azodi, M., DiSilvestro, P., Oza, A., Cristea, M., Berek, J. S., Chan, J. K., Rimel, B. J., Li, Y., Luptakova, K., Clark, R., Matulonis, U. A., & Monk, B. J. (2018). QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii337. https://doi.org/10.1093/annonc/mdy285.152

QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset. / Moore, K. N.; Secord, A. A.; Geller, M. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, 01.10.2018, p. viii337.

Research output: Contribution to journal › Article › peer-review

Moore, KN, Secord, AA, Geller, M, Miller, DS, Cloven, NG, Fleming, GF, Wahner Hendrickson, AE, Azodi, M, DiSilvestro, P, Oza, A, Cristea, M, Berek, JS, Chan, JK, Rimel, BJ, Li, Y, Luptakova, K, Clark, R, Matulonis, UA & Monk, BJ 2018, 'QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii337. https://doi.org/10.1093/annonc/mdy285.152

Moore KN, Secord AA, Geller M, Miller DS, Cloven NG, Fleming GF et al. QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Oct 1;29:viii337. doi: 10.1093/annonc/mdy285.152

@article{a41f8f8fc9b549ec8226f6fde9197066,

title = "QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset",

author = "Moore, {K. N.} and Secord, {A. A.} and M. Geller and Miller, {D. S.} and Cloven, {N. G.} and Fleming, {G. F.} and {Wahner Hendrickson}, {A. E.} and M. Azodi and P. DiSilvestro and A. Oza and M. Cristea and Berek, {J. S.} and Chan, {J. K.} and Rimel, {B. J.} and Y. Li and K. Luptakova and R. Clark and Matulonis, {U. A.} and Monk, {B. J.}",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy285.152",

language = "English (US)",

volume = "29",

pages = "viii337",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - QUADRA

T2 - A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset

AU - Moore, K. N.

AU - Secord, A. A.

AU - Geller, M.

AU - Miller, D. S.

AU - Cloven, N. G.

AU - Fleming, G. F.

AU - Wahner Hendrickson, A. E.

AU - Azodi, M.

AU - DiSilvestro, P.

AU - Oza, A.

AU - Cristea, M.

AU - Berek, J. S.

AU - Chan, J. K.

AU - Rimel, B. J.

AU - Li, Y.

AU - Luptakova, K.

AU - Clark, R.

AU - Matulonis, U. A.

AU - Monk, B. J.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85068308386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068308386&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy285.152

DO - 10.1093/annonc/mdy285.152

M3 - Article

C2 - 32136795

SN - 0923-7534

VL - 29

SP - viii337

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this